SynOx Therapeutics, a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody directed against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumours (TGCT), has appointed Professor Ton Logtenberg as…
SynOx Therapeutics, a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody directed against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumours (TGCT), has appointed Professor Ton Logtenberg as…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference


